表紙
市場調查報告書

傳染病分子診斷的全球市場:影響和預測,分析COVID-19,2021-2025

Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2021-2025

出版商 Howe Sound Research 商品編碼 969250
出版日期 內容資訊 英文 445 Pages
商品交期: 最快1-2個工作天內
價格
傳染病分子診斷的全球市場:影響和預測,分析COVID-19,2021-2025 Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2021-2025
出版日期: 2020年11月04日內容資訊: 英文 445 Pages
簡介

本報告調查了全球傳染病分子診斷市場,包括按疾病進行的市場分析,行業概況,主要公司的概況,市場趨勢,最新趨勢,全球市場概況,綜合症,我們提供信息,例如按基因序列數量和測試位置進行分析。

此報告的關鍵字

<身體>
  • 生物標誌物
  • 診斷
  • 分析
  • 體外診斷
  • 醫學研究所
  • 體檢
  • 體外診斷
  • 多重
  • 血液感染
  • 敗血症
  • 性病
  • 性感染
  • 護理點
  • POC
  • DNA
  • RNA
  • 綜合徵
  • 呼吸
  • 胃腸道
  • 胃腸道
  • 腸胃炎
  • 腦膜炎
  • CNS
  • 中樞神經系統
  • mRNA
  • 轉錄組
  • 臨床實驗室
  • POL
  • 快速檢查
  • 快速診斷
  • 臨床實驗室
  • COVID

目錄

i。傳染病的分子診斷-策略狀況分析和COVID-19的影響

ii。高管,營銷,銷售和業務開發人員指南

iii。管理顧問和投資顧問指南

第1章市場介紹和定義

第2章按疾病進行的市場分析

  • HIV人免疫缺陷病毒(AIDS)
    • 病毒學
    • 診斷
    • 測試
    • 市場機會分析
  • HBV-B肝炎
    • 病毒學
    • 機制
    • 診斷
    • 市場機會分析
  • HCV-C肝炎
    • 分類方法
    • 結構
    • 分子生物學
    • 重複
    • 基因型
    • 市場機會分析
  • HPV人乳頭瘤病毒
    • 病毒學
    • 診斷
    • 市場機會分析
  • 流感
    • 病毒學
    • 檢驗
    • 市場機會分析
  • CTGC-衣原體/山羊
    • 山羊
    • 衣原體
    • 檢驗
    • 市場機會分析
  • 肺結核
    • 分枝桿菌
    • 診斷
    • 流行病學
    • 分子診斷測試
    • 市場機會分析
  • MRSA-耐甲氧西林的黃色葡萄球菌
    • 診斷
    • FDA批准的分子測試
    • 市場機會分析
  • VRE-萬古黴素耐藥腸桿菌
    • FDA批准的VRE分子診斷測試
    • 市場機會分析
  • 血液篩查
    • 收集和檢查
    • FDA批准的多元測定
    • 市場機會分析
  • COVID-19(新的冠狀病毒感染)
    • 體徵和症狀
    • 感染
    • 診斷
    • 預防
    • 管理
    • 預後
  • 大流行診斷
    • 風險管理:感染迅速傳播
    • 診斷技術:基於核酸
    • 診斷技術:免疫測定和血清學
    • 上市時間和準備工作問題
    • 多重傳播在大流行管理中的作用尚未得到認識

第3章行業概述

  • 相關組織
    • 學術研究所
    • 診斷測試開發人員
    • 儀器供應商
    • 分銷商和試劑供應商
    • 獨立檢查機構
    • 公共檢查機構
    • 醫院實驗室
    • 臨床實驗室
    • 審計機構
    • 認證機構
  • 臨床測試市場領域
  • 產業結構
  • 主要公司簡介
    • Abbott Diagnostics
    • Accelerate Diagnostics
    • Ador Diagnostics
    • Akonni Biosystems
    • Alveo Technologies
    • Applied BioCode
    • Atlas Genetics
    • Aus Diagnostics
    • BD Diagnostics
    • Beckman Coulter
    • Biocartis
    • bioMrieux
    • Bio-Rad Laboratories
    • Bosch Healthcare Solutions GmbH
    • Cepheid
    • Chembio
    • Curetis
    • Diagenode Diagnostics
    • DiaSorin
    • Eiken Chemical
    • Fusion Genomics.
    • Genedrive
    • GenePOC Diagnostics
    • GenMark Dx
    • Grifols
    • Hologic
    • Illumina
    • Inflammatix
    • Janssen Diagnostics
    • Karius
    • Lexagene
    • Luminex
    • Mbio Diagnostics
    • Meridian Bioscience
    • Mesa Biotech
    • Mobidiag
    • Nanomix
    • Oxford Nanopore Technologies
    • Panagene
    • Primerdesign
    • Prominex
    • Qiagen
    • Quantumdx
    • Quidel
    • Roche Molecular Diagnostics
    • Seegene
    • Siemens Healthineers
    • SpeeDx
    • T2 Biosystems
    • Thermo Fisher
    • Veramarx
    • XCR Diagnostics

第4章市場趨勢

  • 生長促進劑
  • 生長抑製劑
  • 儀表和自動化
  • 診斷技術的發展

第5章最新趨勢

第6章世界市場

  • 各國市場概況
  • 按綜合徵分類的市場概況
  • 基因序列數量的市場概況
  • 檢驗地點的市場概況

第7章綜合症市場

  • 呼吸
  • 胃腸道
  • 腦膜炎/腦炎
  • 性感染
  • 其他

第8章按基因序列數量劃分的市場

  • 單重
  • 雙工
  • 三層
  • 多重

第9章按檢驗地點劃分的市場

  • 醫院實驗室
  • 門診實驗室
  • POC
  • 其他

附錄

  • i。美國醫療保險制度:2020年臨床檢查費用表
  • II。批准的COVID-19分析
目錄

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab my disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is a member of The American Association for Clinical Chemistry. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research - Burke Institute

Finance for Senior Executives - Harvard Business School

KEYWORDS for this report

  • biomarkers
  • diagnostic
  • assay
  • in vitro diagnostics
  • medical laboratory
  • medical tests
  • IVD
  • multiplex
  • blood infection
  • sepsis
  • STD
  • sexually transmitted
  • point of care
  • POC
  • DNA
  • RNA
  • syndrome
  • respiratory
  • GI
  • gastrointestinal
  • gastroenteritis
  • meningitis
  • CNS
  • central nervous system
  • mRNA
  • transcriptome
  • physician office lab
  • POL
  • rapid testing
  • rapid diagnostics
  • Clinical laboratory
  • COVID

Table of Contents

i. Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19.

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What is Molecular Diagnostics
  • 1.2 The Diagnostics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenues
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Market Analysis by Disease

  • 2.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 2.1.1 Virology
      • 2.1.1.1 Classification
      • 2.1.1.2 Structure and genome
      • 2.1.1.3 Tropism
      • 2.1.1.4 Replication cycle
      • 2.1.1.5 Genetic variability
    • 2.1.2 Diagnosis
    • 2.1.3 Testing
      • 2.1.3.1 Antibody tests
      • 2.1.3.2 Point of Care Tests (POCT)
      • 2.1.3.4 Antigen Tests
      • 2.1.3.5 Nucleic acid-based tests (NAT)
      • 2.1.3.6 Other tests used in HIV treatment
    • 2.1.4 Market Opportunity Analysis
  • 2.2 HBV - Hepatitis B
    • 2.2.1 Virology
      • 2.2.1.1 Genome
      • 2.2.1.2 Pathogenesis
      • 2.2.1.3 Hepatitis B virus replication
      • 2.2.1.4 Serotypes and genotypes
    • 2.2.2 Mechanisms
    • 2.2.3 Diagnosis
    • 2.2.4 Market Opportunity Analysis
  • 2.3 HCV - Hepatitis C
    • 2.3.1 Taxonomy
    • 2.3.2 Structure
      • 2.3.2.2 Genome
    • 2.3.3 Molecular biology
    • 2.3.4 Replication
    • 2.3.5 Genotypes
      • 2.3.5.1 Clinical importance
    • 2.3.6 Market Opportunity Analysis
  • 2.4 HPV - Human papillomavirus
    • 2.4.1 Virology
      • 2.4.1.1 E6/E7 proteins
      • 2.4.1.2 Role in cancer
      • 2.4.1.3 E2 research
      • 2.4.1.4 Latency period
      • 2.4.1.5 Clearance
    • 2.4.2 Diagnosis
      • 2.4.2.1 Cervical testing
      • 2.4.2.2 Oral testing
      • 2.4.2.3 Testing men
      • 2.4.2.4 Other testing
    • 2.4.3 Market Opportunity Analysis
  • 2.5 Influenza
    • 2.5.1 Virology
      • 2.5.1.1 Types of virus
      • 2.5.1.2 Influenzavirus A
      • 2.5.1.3 Influenzavirus B
      • 2.5.1.4 Influenzavirus C
      • 2.5.1.5 Structure, properties, and subtype nomenclature
      • 2.5.1.6 Replication
    • 2.5.2 Testing
      • 2.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 2.5.3 Market Opportunity Analysis
  • 2.6 CTGC - Chlamydia/Gonorhea
    • 2.6.1 Gonorrhea
      • 2.6.1.1 Diagnosis
      • 2.6.1.2 Screening
    • 2.6.2 Chlamydia
      • 2.6.2.1 Diagnosis
      • 2.6.2.2 Screening
    • 2.6.3 Testing
      • 2.6.3.1 Nucleic acid amplification tests (NAATs).
      • 2.6.3.2 Performance of NAAT Tests
    • 2.6.4 Market Opportunity Analysis
  • 2.7 Tuberculosis
    • 2.7.1 Mycobacteria
    • 2.7.2 Diagnosis
      • 2.7.2.1 Active tuberculosis
      • 2.7.2.2 Latent tuberculosis
    • 2.7.3 Epidemiology
    • 2.7.4 Molecular Diagnostic Tests
    • 2.7.5 Market Opportunity Analysis
  • 2.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 2.8.1 Diagnosis
    • 2.8.2 FDA Approved Molecular Tests
    • 2.8.3 Market Opportunity Analysis
  • 2.9 VRE - Vancomycin-resistant Enterococcus
    • 2.9.1 FDA Approved MDx Tests for VRE
    • 2.9.2 Market Opportunity Analysis
  • 2.10 Blood Screening
    • 2.10.1 Collection and Testing
    • 2.10.2 FDA Approved Multiplex Assays
    • 2.10.3 Market Opportunity Analysis
  • 2.11 COVID-19
    • 2.11.1 Signs and symptoms
    • 2.11.2 Transmission
    • 2.11.3 Diagnosis
    • 2.11.4 Prevention
    • 2.11.5 Management
    • 2.11.6 Prognosis
  • 2.12 Pandemic Diagnostics
    • 2.12.1 Risk Management - Spark and Spread
    • 2.12.2 Dx Technology - Nucleic Acid Based
    • 2.12.3 Dx Technology - Immunoassay & Serology
    • 2.12.4 Time to Market and Preparedness Issues
    • 2.12.5 Unrecognized Role of Multiplex in Pandemic Mangement

3. Industry Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Instrumentation Supplier
    • 3.1.4 Distributor and Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Office Labs
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body
  • 3.2 The Clinical Laboratory Market Segments
    • 3.2.1 Traditional Market Segmentation
    • 3.2.2 Laboratory Focus and Segmentation
  • 3.3 Industry Structure
    • 3.3.1 Hospital Testing Share
    • 3.3.2 Economies of Scale
      • 3.3.2.1 Hospital vs. Central Lab
    • 3.3.3 Physician Office Lab's
    • 3.3.4 Physician's and POCT
  • 3.4 Profiles of Key MDx Companies
    • Abbott Diagnostics
    • Accelerate Diagnostics
    • Ador Diagnostics
    • Akonni Biosystems
    • Alveo Technologies
    • Applied BioCode
    • Atlas Genetics
    • Aus Diagnostics
    • BD Diagnostics
    • Beckman Coulter
    • Biocartis
    • bioMérieux
    • Bio-Rad Laboratories
    • Bosch Healthcare Solutions GmbH
    • Cepheid
    • Chembio
    • Curetis
    • Diagenode Diagnostics
    • DiaSorin
    • Eiken Chemical
    • Fusion Genomics.
    • Genedrive
    • GenePOC Diagnostics
    • GenMark Dx
    • Grifols
    • Hologic
    • Illumina
    • Inflammatix
    • Janssen Diagnostics
    • Karius
    • Lexagene
    • Luminex
    • Mbio Diagnostics
    • Meridian Bioscience
    • Mesa Biotech
    • Mobidiag
    • Nanomix
    • Oxford Nanopore Technologies
    • Panagene
    • Primerdesign
    • Prominex
    • Qiagen
    • Quantumdx
    • Quidel
    • Roche Molecular Diagnostics
    • Seegene
    • Siemens Healthineers
    • SpeeDx
    • T2 Biosystems
    • Thermo Fisher
    • Veramarx
    • XCR Diagnostics

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 New Genotypes Creating New Markets
    • 4.1.2 Aging Population a Boon for All Diagnostics
    • 4.1.3 Developing World Driving ID Dx Growth
    • 4.1.4 Point of Care - Why Centralization is Losing Steam
    • 4.1.5 Self Testing
    • 4.1.6 The Need for Speed
    • 4.1.7 The COVID Pandemic
  • 4.2 Factors Limiting Growth
    • 4.2.1 Lower Costs
    • 4.2.2 Infectious Disease is Declining
    • 4.2.3 Wellness Hurts
    • 4.2.4 Economic Growth improves Living Standards
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 The Shrinking Machine.
    • 4.3.2 Multiplex, Point of Care and The Speed Factor
  • 4.4 Diagnostic Technology Development
    • 4.4.1 The Sepsis Testing Market - A New Direction?
    • 4.4.2 POCT/Self Testing as a Disruptive Force
    • 4.4.3 The Genetics Play - One Test for All Known Infections
    • 4.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

5. Molecular Dx - Infectious Disease Recent Developments

  • Recent Developments - Importance and How to Use This Section
    • Importance of These Developments
    • How to Use This Section
      • Scanogen Developing 90 Minute Infection Test
      • Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
      • FDA Provides Self Testing SARS-CoV-2 EAU Guidance
      • Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
      • Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
      • Qiagen Respiratory Panel with Coronavirus Receives CE Mark
      • Lumos Diagnostics Closes $15M Series A Funding
      • Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
      • New Genomic Tests Diagnose Deadly Infections Faster
      • Biotia Raises $2.4M Seed Round
      • STDs resurge in US
      • Ares Genetics signs R&D agreement with leading global IVD corporation
      • Cell-Free DNA Used for Infectious Disease Testing
      • One BioMed Raises $5M
      • FDA grants Qiagen clearance for syndromic testing system
      • iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays
      • Researchers Launch CRISPR Dx Firm Sherlock Biosciences
      • Israel's BATM to Invest up to $30M in Ador Diagnostics
      • Superbug Test from Mobidiag Gets CE Mark
      • Akonni Biosystems Submits Multiplex Diagnostics System to FDA
      • Mesa Biotech RSV Test Wins CE Mark
      • Karius Test to Be Available in Brazil
      • Panagene's STD kit gains Approval
      • Startup Prominex Raises $4M in Series A1
      • GenePOC's Investment Validated by Medicare Decision
      • GenePOC® launches its GenePOC® CDiff test in Canada
      • NYU researchers adapt HIV test to Zika virus
      • Bruker to Acquire Majority Stake in Infectious Disease MDx Firm Hain
      • Applied BioCode's Syndromic Gastrointestinal Pathogen Panel Approved by the FDA
      • Ares Genetics to develop AI diagnostic test for infectious diseases

6. The Global Market for Molecular Diagnostics Infectious Disease

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Syndrome - Overview
    • 6.2.1 Table - Global Market by Syndrome
    • 6.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Syndrome - Base Year
    • 6.2.4 Chart - Global Market by Syndrome - End Year
    • 6.2.5 Chart - Global Market by Syndrome - Share by Year
    • 6.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 6.3 Global Market by Plex - Overview
    • 6.3.1 Table - Global Market by Plex
    • 6.3.2 Chart - Global Market by Plex - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market by Plex - Base Year
    • 6.3.4 Chart - Global Market by Plex - End Year
    • 6.3.5 Chart - Global Market by Plex - Share by Year
    • 6.3.6 Chart - Global Market by Plex - Segments Growth
  • 6.4 Global Market by Place - Overview
    • 6.4.1 Table - Global Market by Place
    • 6.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 6.4.3 Chart - Global Market by Place - Base Year
    • 6.4.4 Chart - Global Market by Place - End Year
    • 6.4.5 Chart - Global Market by Place - Share by Year
    • 6.4.6 Chart - Global Market by Place - Segments Growth

7. Global MDx Infectious Disease Markets - By Syndrome

  • 7.1 Respiratory
    • 7.1.1 Table Respiratory - by Country
    • 7.1.2 Chart - Respiratory Growth
  • 7.2 Gastrointestinal
    • 7.2.1 Table Gastrointestinal - by Country
    • 7.2.2 Chart - Gastrointestinal Growth
  • 7.3 Blood
    • 7.3.1 Table Blood - by Country
    • 7.3.2 Chart - Blood Growth
  • 7.4 Meningitis/Encephalitis
    • 7.4.1 Table Meningitis/Encephalitis - by Country
    • 7.4.2 Chart - Meningitis/Encephalitis Growth
  • 7.5 Sexually Transmitted Disease
    • 7.5.1 Table Sexually Transmitted Disease - by Country
    • 7.5.2 Chart - Sexually Transmitted Disease Growth
  • 7.6 Other
    • 7.6.1 Table Other - by Country
    • 7.6.2 Chart - Other Growth

8. Global MDx Markets for Infectious Disease - by Plex

  • 8.1 Single Plex
    • 8.1.1 Table Single Plex - by Country
    • 8.1.2 Chart - Single Plex Growth
  • 8.2 Duplex
    • 8.2.1 Table Duplex - by Country
    • 8.2.2 Chart - Duplex Growth
  • 8.3 Triplex
    • 8.3.1 Table Triplex - by Country
    • 8.3.2 Chart - Triplex Growth
  • 8.4 Multiplex Technology
    • 8.4.1 Table Multiplex - by Country
    • 8.4.2 Chart - Multiplex Growth

9. Global MDx Infectious Disease Markets - by Place

  • 9.1 Hospital Lab
    • 9.1.1 Table Hospital Lab - by Country
    • 9.1.2 Chart - Hospital Lab Growth
  • 9.2 Outpatient Lab
    • 9.2.1 Table Outpatient Lab - by Country
    • 9.2.2 Chart - Outpatient Lab Growth
  • 9.3 POC
    • 9.3.1 Table POC - by Country
    • 9.3.2 Chart - POC Growth
  • 9.4 Other Technology
    • 9.4.1 Table Other - by Country
    • 9.4.2 Chart - Other Growth

Appendices

  • I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
  • II. COVID-19 Approved Assays

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 2 Classification of HIV Species
  • Table 3 HIV Tests - CMS Codes & Prices
  • Table 4 Current HIV Molecular Tests and Instruments Used
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 CTGC Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 FDA Approved Multiplex Assays
  • Table 23 Characteristics of Coronavirus Pandemic Infections
  • Table 24 COVID-19 Symptoms
  • Table 25 Market Players by Type
  • Table 26 Clinical Laboratory Departments and Segments
  • Table 27 Laboratory Management Focus - Different Approaches
  • Table 28 Key Segmentation Variables Going Forward
  • Table 29 Five Factors Driving Growth
  • Table 30 Four Factors Limiting Growth
  • Table 31 Key Diagnostic Laboratory Technology Trends
  • Table 32 - Global Market by Region
  • Table 33 Global Market by Syndrome
  • Table 34 Global Market by Plex
  • Table 35 Global Market by Place
  • Table 36 Respiratory by Country
  • Table 37 Gastrointestinal by Country
  • Table 38 Blood by Country
  • Table 39 Meningitis/Encephalitis by Country
  • Table 40 Sexually Transmitted Disease by Country
  • Table 41 Other by Country
  • Table 42 Single Plex by Country
  • Table 43 Duplex by Country
  • Table 44 Triplex by Country
  • Table 45 Multiplex by Country
  • Table 46 Hospital Lab by Country
  • Table 47 Outpatient Lab by Country
  • Table 48 POC by Country
  • Table 49 Other by Country
  • Table 50 2020 Clinical Lab Fee Schedule
  • Table 51 COVID -19 Approved Assays

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 2 HIV Virion
  • Figure 3 Diagram of the HIV Replication Cycle
  • Figure 4 The Structure of the HBV Virus
  • Figure 5 Hepatitis B Replication
  • Figure 6 Structure of the HCV Virus
  • Figure 7 HCV Replication Cycle
  • Figure 8 Structure of the Influenza Virion
  • Figure 9 Influenza Replication
  • Figure 10 Scanning Electronmicrograph of Tuberculosis
  • Figure 11 Percentage of World Population Over 65
  • Figure 12 Chart Infectious Disease Decline
  • Figure 13 Global Market Shares Chart
  • Figure 14 Global Market by Syndrome - Base vs. Final
  • Figure 15 Global Market by Syndrome Base Year
  • Figure 16 Global Market by Syndrome End Year
  • Figure 17 Syndrome Share by Year
  • Figure 18 Syndrome Segments Growth
  • Figure 19 Global Market by Plex - Base vs. Final
  • Figure 20 Global Market by Plex Base Year
  • Figure 21 Global Market by Plex End Year
  • Figure 22 Plex Share by Year
  • Figure 23 Plex Segments Growth
  • Figure 24 Global Market by Place - Base vs. Final
  • Figure 25 Global Market by Place Base Year
  • Figure 26 Global Market by Place End Year
  • Figure 27 Place Share by Year
  • Figure 28 Place Segments Growth
  • Figure 29 Respiratory Growth
  • Figure 30 Gastrointestinal Diagnostics Growth
  • Figure 31 Blood Growth
  • Figure 32 Meningitis/Encephalitis Growth
  • Figure 33 Sexually Transmitted Disease Growth
  • Figure 34 Other Growth
  • Figure 35 Single Plex Growth
  • Figure 36 Duplex Growth
  • Figure 37 Triplex Growth
  • Figure 38 Multiplex Growth
  • Figure 39 Hospital Lab Growth
  • Figure 40 Outpatient Lab Growth
  • Figure 41 POC Growth
  • Figure 42 Other Growth